<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35435727</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1098-5522</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>90</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Infection and immunity</Title>
          <ISOAbbreviation>Infect Immun</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lipidation of <i>Haemophilus influenzae</i> Antigens P6 and OMP26 Improves Immunogenicity and Protection against Nasopharyngeal Colonization and Ear Infection.</ArticleTitle>
        <Pagination>
          <StartPage>e0067821</StartPage>
          <MedlinePgn>e0067821</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e00678-21</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1128/iai.00678-21</ELocationID>
        <Abstract>
          <AbstractText>Nontypeable Haemophilus influenzae (NTHi) causes respiratory infections that lead to high morbidity and mortality worldwide, encouraging development of effective vaccines. To achieve a protective impact on nasopharyngeal (NP) colonization by NTHi, enhanced immunogenicity beyond that achievable with recombinant-protein antigens is likely to be necessary. Adding a lipid moiety to a recombinant protein would enhance immunogenicity through Toll-like receptor 2 signaling of antigen-presenting cells and Th17 cell response in the nasal-associated lymphoid tissue (NALT). We investigated effects of lipidation (L) of recombinant proteins P6 and OMP26 compared to nonlipidated (NL) P6 and OMP26 and as fusion constructs (L-OMP26ϕNL-P6 and L-P6ϕNL-OMP26) in a mouse model. After intraperitoneal or intranasal vaccination, antibody responses were compared and protection from NP colonization and middle ear infection were assessed. L-P6 and L-OMP26 induced approximately 10- to 100-fold-higher IgG antibody levels than NL-P6 and NL-OMP26. Fusion constructs significantly increased IgG antibody to both target proteins, even though only one of the proteins was lipidated. NP colonization and middle ear bullae NTHi density was 1 to 4 logs lower following vaccination with L-P6 and L-OMP26 than with NL-P6 and NL-OMP26. Fusion constructs also resulted in a 1- to 3-log-lower NTHi density following vaccination. NALT cells from mice vaccinated with lipidated protein constructs had higher levels of interleukin-17 (IL-17), IL-22, and CD4<sup>+</sup> T-cell memory. Passive transfer of sera from L-OMP26ϕNL-P6-vaccinated mice to recipient infant mice reduced NP colonization and ear bulla NTHi density. We conclude that L-P6, L-OMP26, and fusion constructs generate enhanced antibody responses and protection from NP colonization and middle ear infection by NTHi in mice.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kaur</LastName>
            <ForeName>Ravinder</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0001-6539-5339</Identifier>
            <AffiliationInfo>
              <Affiliation>Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pichichero</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Infect Immun</MedlineTA>
        <NlmUniqueID>0246127</NlmUniqueID>
        <ISSNLinking>0019-9567</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000907">Antibodies, Bacterial</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000942">Antigens, Bacterial</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001425">Bacterial Outer Membrane Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018073">Haemophilus Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000907" MajorTopicYN="N">Antibodies, Bacterial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000942" MajorTopicYN="N">Antigens, Bacterial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001425" MajorTopicYN="N">Bacterial Outer Membrane Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006192" MajorTopicYN="Y">Haemophilus Infections</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018073" MajorTopicYN="Y">Haemophilus Vaccines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006193" MajorTopicYN="N">Haemophilus influenzae</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010033" MajorTopicYN="Y">Otitis Media</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Haemophilus influenzae</Keyword>
        <Keyword MajorTopicYN="N">OMP26</Keyword>
        <Keyword MajorTopicYN="N">P6</Keyword>
        <Keyword MajorTopicYN="N">TLR2</Keyword>
        <Keyword MajorTopicYN="N">Th17 immunity</Keyword>
        <Keyword MajorTopicYN="N">acute otitis media</Keyword>
        <Keyword MajorTopicYN="N">antibodies</Keyword>
        <Keyword MajorTopicYN="N">lipidated recombinant proteins</Keyword>
        <Keyword MajorTopicYN="N">nasopharyngeal colonization</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare a conflict of interest. Rochester regional health has made US-patent application and author Michael Pichichero is the inventor regarding the lipidated and fusion constructs. Ravinder Kaur has no conflict to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>12</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35435727</ArticleId>
        <ArticleId IdType="pmc">PMC9119059</ArticleId>
        <ArticleId IdType="doi">10.1128/iai.00678-21</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kaur R, Morris M, Pichichero ME. 2017. Epidemiology of acute otitis media in the postpneumococcal conjugate vaccine era. Pediatrics
140. 10.1542/peds.2017-0181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2017-0181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casey JR, Adlowitz DG, Pichichero ME. 2010. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J
29:304–309. 10.1097/INF.0b013e3181c1bc48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0b013e3181c1bc48</ArticleId>
            <ArticleId IdType="pmc">PMC3959886</ArticleId>
            <ArticleId IdType="pubmed">19935445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur R, Casey JR, Pichichero ME. 2013. Relationship with original pathogen in recurrence of acute otitis media after completion of amoxicillin/clavulanate: bacterial relapse or new pathogen. Pediatr Infect Dis J
32:1159–1162. 10.1097/INF.0b013e31829e3779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0b013e31829e3779</ArticleId>
            <ArticleId IdType="pmc">PMC3845822</ArticleId>
            <ArticleId IdType="pubmed">23736142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barkai G, Leibovitz E, Givon-Lavi N, Dagan R. 2009. Potential contribution by nontypeable Haemophilus influenzae in protracted and recurrent acute otitis media. Pediatr Infect Dis J
28:466–471. 10.1097/INF.0b013e3181950c74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0b013e3181950c74</ArticleId>
            <ArticleId IdType="pubmed">19504729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein JO. 1997. Role of nontypeable Haemophilus influenzae in pediatric respiratory tract infections. Pediatr Infect Dis J
16:S5–S8. 10.1097/00006454-199702001-00002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00006454-199702001-00002</ArticleId>
            <ArticleId IdType="pubmed">9041620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Eldere J, Slack MP, Ladhani S, Cripps AW. 2014. Non-typeable Haemophilus influenzae, an under-recognized pathogen. Lancet Infect Dis
14:1281–1292. 10.1016/S1473-3099(14)70734-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(14)70734-0</ArticleId>
            <ArticleId IdType="pubmed">25012226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swords WE. 2012. Nontypeable Haemophilus influenzae biofilms: role in chronic airway infections. Front Cell Infect Microbiol
2:97. 10.3389/fcimb.2012.00097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcimb.2012.00097</ArticleId>
            <ArticleId IdType="pmc">PMC3417564</ArticleId>
            <ArticleId IdType="pubmed">22919686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alikhan MM, Lee FE. 2014. Understanding nontypeable Haemophilus influenzae and chronic obstructive pulmonary disease. Curr Opin Pulm Med
20:159–164. 10.1097/MCP.0000000000000023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MCP.0000000000000023</ArticleId>
            <ArticleId IdType="pubmed">24441573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallejo JG, McNeil JC, Hulten KG, Sommer LM, Dunn JJ, Kaplan SL. 2019. Invasive Haemophilus influenzae disease at Texas Children’s Hospital, 2011 to 2018. Pediatr Infect Dis J
38:900–905. 10.1097/INF.0000000000002383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0000000000002383</ArticleId>
            <ArticleId IdType="pubmed">31107422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Resman F, Ristovski M, Ahl J, Forsgren A, Gilsdorf JR, Jasir A, Kaijser B, Kronvall G, Riesbeck K. 2011. Invasive disease caused by Haemophilus influenzae in Sweden 1997-2009; evidence of increasing incidence and clinical burden of non-type b strains. Clin Microbiol Infect
17:1638–1645. 10.1111/j.1469-0691.2010.03417.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1469-0691.2010.03417.x</ArticleId>
            <ArticleId IdType="pubmed">21054663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara N, Wajima T, Seyama S, Tanaka E, Shirai A, Shibata M, Natsume Y, Shiro H, Noguchi N. 2019. Isolation of multidrug-resistant Haemophilus influenzae harboring multiple exogenous genes from a patient diagnosed with acute sinusitis. J Infect Chemother
25:385–387. 10.1016/j.jiac.2018.09.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jiac.2018.09.015</ArticleId>
            <ArticleId IdType="pubmed">30482699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deghmane AE, Hong E, Chehboub S, Terrade A, Falguieres M, Sort M, Harrison O, Jolley KA, Taha MK. 2019. High diversity of invasive Haemophilus influenzae isolates in France and the emergence of resistance to third generation cephalosporins by alteration of the ftsI gene. J Infect
79:7–14. 10.1016/j.jinf.2019.05.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jinf.2019.05.007</ArticleId>
            <ArticleId IdType="pubmed">31100360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke C, Bakaletz LO, Ruiz-Guinazu J, Borys D, Mrkvan T. 2017. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage. Expert Rev Vaccines
16:1–14. 10.1080/14760584.2017.1333905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14760584.2017.1333905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandileone M-C. d C, Zanella RC, Almeida SCG, Brandao AP, Ribeiro AF, Carvalhanas T-RMP, Sato H, Andrade A-L, Verani JR, Guerra M-LLS, do Prado LS, Bokermann S, Lemos A-PS, Gorla M-CO, Liphaus B, Policena G, da Glória Carvalho M, Sato A-PS, Nerger M-L, Conde MT, Pneumococcal Carriage Study Group. 2016. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in Sao Paulo. Brazil Vaccine
34:5604–5611. 10.1016/j.vaccine.2016.09.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2016.09.027</ArticleId>
            <ArticleId IdType="pubmed">27692770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van den Bergh MR, Spijkerman J, Swinnen KM, Francois NA, Pascal TG, Borys D, Schuerman L, Ijzerman EP, Bruin JP, van der Ende A, Veenhoven RH, Sanders EA. 2013. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis
56:e30–e39. 10.1093/cid/cis922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/cis922</ArticleId>
            <ArticleId IdType="pmc">PMC3540043</ArticleId>
            <ArticleId IdType="pubmed">23118268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leroux-Roels G, Van Damme P, Haazen W, Shakib S, Caubet M, Aris E, Devaster JM, Peeters M. 2016. Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. Vaccine
34:3156–3163. 10.1016/j.vaccine.2016.04.051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2016.04.051</ArticleId>
            <ArticleId IdType="pubmed">27133877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Damme P, Leroux-Roels G, Vandermeulen C, De Ryck I, Tasciotti A, Dozot M, Moraschini L, Testa M, Arora AK. 2019. Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine. Vaccine
37:3113–3122. 10.1016/j.vaccine.2019.04.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2019.04.041</ArticleId>
            <ArticleId IdType="pubmed">31029515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilkinson TMA, Schembri S, Brightling C, Bakerly ND, Lewis K, MacNee W, Rombo L, Hedner J, Allen M, Walker PP, De Ryck I, Tasciotti A, Casula D, Moris P, Testa M, Arora AK. 2019. Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: a phase 2 clinical trial. Vaccine
37:6102–6111. 10.1016/j.vaccine.2019.07.100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2019.07.100</ArticleId>
            <ArticleId IdType="pubmed">31447126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur R, Casey JR, Pichichero ME. 2011. Serum antibody response to three non-typeable Haemophilus influenzae outer membrane proteins during acute otitis media and nasopharyngeal colonization in otitis prone and non-otitis prone children. Vaccine
29:1023–1028. 10.1016/j.vaccine.2010.11.055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2010.11.055</ArticleId>
            <ArticleId IdType="pmc">PMC3042269</ArticleId>
            <ArticleId IdType="pubmed">21129398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur R, Casey JR, Pichichero ME. 2011. Serum antibody response to five Streptococcus pneumoniae proteins during acute otitis media in otitis-prone and non-otitis-prone children. Pediatr Infect Dis J
30:645–650. 10.1097/INF.0b013e31821c2d8b.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0b013e31821c2d8b</ArticleId>
            <ArticleId IdType="pmc">PMC3296524</ArticleId>
            <ArticleId IdType="pubmed">21487325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren D, Almudevar AL, Murphy TF, Lafontaine ER, Campagnari AA, Luke-Marshall N, Pichichero ME. 2019. Serum antibody response to Moraxella catarrhalis proteins in stringently defined otitis prone children. Vaccine
37:4637–4645. 10.1016/j.vaccine.2017.07.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.07.027</ArticleId>
            <ArticleId IdType="pmc">PMC5785584</ArticleId>
            <ArticleId IdType="pubmed">28755833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pichichero ME, Casey JR, Almudevar A, Basha S, Surendran N, Kaur R, Morris M, Livingstone AM, Mosmann TR. 2016. Functional immune cell differences associated with low vaccine responses in infants. J Infect Dis
213:2014–2019. 10.1093/infdis/jiw053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiw053</ArticleId>
            <ArticleId IdType="pmc">PMC4878722</ArticleId>
            <ArticleId IdType="pubmed">26908730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy TF, Faden H, Bakaletz LO, Kyd JM, Forsgren A, Campos J, Virji M, Pelton SI. 2009. Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J
28:43–48. 10.1097/INF.0b013e318184dba2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0b013e318184dba2</ArticleId>
            <ArticleId IdType="pubmed">19057458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poolman JT, Bakaletz L, Cripps A, Denoel PA, Forsgren A, Kyd J, Lobet Y. 2000. Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. Vaccine
19:S108–S115. 10.1016/S0264-410X(00)00288-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0264-410X(00)00288-7</ArticleId>
            <ArticleId IdType="pubmed">11163473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan MN, Ren D, Kaur R, Basha S, Zagursky R, Pichichero ME. 2016. Developing a vaccine to prevent otitis media caused by nontypeable Haemophilus influenzae. Expert Rev Vaccines
15:863–878. 10.1586/14760584.2016.1156539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14760584.2016.1156539</ArticleId>
            <ArticleId IdType="pubmed">26894630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy TF. 2015. Vaccines for nontypeable Haemophilus influenzae: the future is now. Clin Vaccine Immunol
22:459–466. 10.1128/CVI.00089-15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CVI.00089-15</ArticleId>
            <ArticleId IdType="pmc">PMC4412935</ArticleId>
            <ArticleId IdType="pubmed">25787137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan MN, Kaur R, Pichichero ME. 2012. Bactericidal antibody response against P6, protein D, and OMP26 of nontypeable Haemophilus influenzae after acute otitis media in otitis-prone children. FEMS Immunol Med Microbiol
65:439–447. 10.1111/j.1574-695X.2012.00967.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1574-695X.2012.00967.x</ArticleId>
            <ArticleId IdType="pubmed">22463053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernstein JM, Faden HS, Loos BG, Murphy TF, Ogra PL. 1992. Recurrent otitis media with non-typable Haemophilus influenzae: the role of serum bactericidal antibody. Int J Pediatr Otorhinolaryngol
23:1–13. 10.1016/0165-5876(92)90074-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0165-5876(92)90074-y</ArticleId>
            <ArticleId IdType="pubmed">1592547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foxwell AR, Kyd JM, Cripps AW. 1998. Nontypeable Haemophilus influenzae: pathogenesis and prevention. Microbiol Mol Biol Rev
62:294–308. 10.1128/MMBR.62.2.294-308.1998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MMBR.62.2.294-308.1998</ArticleId>
            <ArticleId IdType="pmc">PMC98916</ArticleId>
            <ArticleId IdType="pubmed">9618443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Q, Casey JR, Newman E, Pichichero ME. 2016. Otitis-prone children have immunologic deficiencies in naturally acquired nasopharyngeal mucosal antibody response after Streptococcus pneumoniae colonization. Pediatr Infect Dis J
35:54–60. 10.1097/INF.0000000000000949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0000000000000949</ArticleId>
            <ArticleId IdType="pubmed">26448450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odutola A, Ota MOC, Antonio M, Ogundare EO, Saidu Y, Foster-Nyarko E, Owiafe PK, Ceesay F, Worwui A, Idoko OT, Owolabi O, Bojang A, Jarju S, Drammeh I, Kampmann B, Greenwood BM, Alderson M, Traskine M, Devos N, Schoonbroodt S, Swinnen K, Verlant V, Dobbelaere K, Borys D. 2017. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: a phase 2, randomized, controlled, observer-blind study. Vaccine
35:2531–2542. 10.1016/j.vaccine.2017.03.071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.03.071</ArticleId>
            <ArticleId IdType="pubmed">28389097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alderson MR, Murphy T, Pelton SI, Novotny LA, Hammitt LL, Kurabi A, Li JD, Thornton RB, Kirkham LS. 2020. Panel 8: vaccines and immunology. Int J Pediatr Otorhinolaryngol
130(Suppl 1):109839. 10.1016/j.ijporl.2019.109839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijporl.2019.109839</ArticleId>
            <ArticleId IdType="pmc">PMC7153269</ArticleId>
            <ArticleId IdType="pubmed">31948716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammitt LL, Campbell JC, Borys D, Weatherholtz RC, Reid R, Goklish N, Moulton LH, Traskine M, Song Y, Swinnen K, Santosham M, O’Brien KL. 2019. Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: a phase IIb randomized study. Vaccine
37:7482–7492. 10.1016/j.vaccine.2019.09.076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2019.09.076</ArticleId>
            <ArticleId IdType="pubmed">31629570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeda K, Kaisho T, Akira S. 2003. Toll-like receptors. Annu Rev Immunol
21:335–376. 10.1146/annurev.immunol.21.120601.141126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.immunol.21.120601.141126</ArticleId>
            <ArticleId IdType="pubmed">12524386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganley-Leal LM, Liu X, Wetzler LM. 2006. Toll-like receptor 2-mediated human B cell differentiation. Clin Immunol
120:272–284. 10.1016/j.clim.2006.04.571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2006.04.571</ArticleId>
            <ArticleId IdType="pubmed">16766226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moffitt K, Skoberne M, Howard A, Gavrilescu LC, Gierahn T, Munzer S, Dixit B, Giannasca P, Flechtner JB, Malley R. 2014. Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteins. Infect Immun
82:2079–2086. 10.1128/IAI.01632-13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.01632-13</ArticleId>
            <ArticleId IdType="pmc">PMC3993436</ArticleId>
            <ArticleId IdType="pubmed">24614661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pichichero ME, Kaur R, Casey JR, Sabirov A, Khan MN, Almudevar A. 2010. Antibody response to Haemophilus influenzae outer membrane protein D, P6, and OMP26 after nasopharyngeal colonization and acute otitis media in children. Vaccine
28:7184–7192. 10.1016/j.vaccine.2010.08.063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2010.08.063</ArticleId>
            <ArticleId IdType="pmc">PMC3959881</ArticleId>
            <ArticleId IdType="pubmed">20800701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green BA, Quinn-Dey T, Zlotnick GW. 1987. Biologic activities of antibody to a peptidoglycan-associated lipoprotein of Haemophilus influenzae against multiple clinical isolates of H. influenzae type b. Infect Immun
55:2878–2883. 10.1128/iai.55.12.2878-2883.1987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.55.12.2878-2883.1987</ArticleId>
            <ArticleId IdType="pmc">PMC260001</ArticleId>
            <ArticleId IdType="pubmed">3316025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kyd JM, Dunkley ML, Cripps AW. 1995. Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect Immun
63:2931–2940. 10.1128/iai.63.8.2931-2940.1995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/iai.63.8.2931-2940.1995</ArticleId>
            <ArticleId IdType="pmc">PMC173399</ArticleId>
            <ArticleId IdType="pubmed">7622215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kyd JM, Cripps AW, Novotny LA, Bakaletz LO. 2003. Efficacy of the 26-kilodalton outer membrane protein and two P5 fibrin-derived immunogens to induce clearance of nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx. Infect Immun
71:4691–4699. 10.1128/IAI.71.8.4691-4699.2003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.71.8.4691-4699.2003</ArticleId>
            <ArticleId IdType="pmc">PMC165997</ArticleId>
            <ArticleId IdType="pubmed">12874350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brito LA, Singh M. 2011. Acceptable levels of endotoxin in vaccine formulations during preclinical research. J Pharm Sci
100:34–37. 10.1002/jps.22267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.22267</ArticleId>
            <ArticleId IdType="pubmed">20575063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ, European MenB Vaccine Study Group. 2012. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA
307:573–582. 10.1001/jama.2012.85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2012.85</ArticleId>
            <ArticleId IdType="pubmed">22318278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen MT, Uebele J, Kumari N, Nakayama H, Peter L, Ticha O, Woischnig AK, Schmaler M, Khanna N, Dohmae N, Lee BL, Bekeredjian-Ding I, Gotz F. 2017. Lipid moieties on lipoproteins of commensal and non-commensal staphylococci induce differential immune responses. Nat Commun
8:2246. 10.1038/s41467-017-02234-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-02234-4</ArticleId>
            <ArticleId IdType="pmc">PMC5740139</ArticleId>
            <ArticleId IdType="pubmed">29269769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinon-Torres F, Gimenez-Sanchez F, Bernaola-Iturbe E, Diez-Domingo J, Jiang Q, Perez JL. 2014. A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants. Vaccine
32:5206–5211. 10.1016/j.vaccine.2014.07.049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2014.07.049</ArticleId>
            <ArticleId IdType="pubmed">25077420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan AQ, Chen Q, Wu ZQ, Paton JC, Snapper CM. 2005. Both innate immunity and type 1 humoral immunity to Streptococcus pneumoniae are mediated by MyD88 but differ in their relative levels of dependence on Toll-like receptor 2. Infect Immun
73:298–307. 10.1128/IAI.73.1.298-307.2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.73.1.298-307.2005</ArticleId>
            <ArticleId IdType="pmc">PMC538967</ArticleId>
            <ArticleId IdType="pubmed">15618166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu CL, Yu YL, Kung YC, Liao PY, Liu KJ, Tseng YT, Lin YC, Hsieh SS, Chong PC, Yang CY. 2012. The immunomodulatory activity of meningococcal lipoprotein Ag473 depends on the conformation made up of the lipid and protein moieties. PLoS One
7:e40873. 10.1371/journal.pone.0040873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0040873</ArticleId>
            <ArticleId IdType="pmc">PMC3402496</ArticleId>
            <ArticleId IdType="pubmed">22844415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voss F, Kohler TP, Meyer T, Abdullah MR, van Opzeeland FJ, Saleh M, Michalik S, van Selm S, Schmidt F, de Jonge MI, Hammerschmidt S. 2018. Intranasal vaccination with lipoproteins confers protection against pneumococcal colonization. Front Immunol
9:2405. 10.3389/fimmu.2018.02405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.02405</ArticleId>
            <ArticleId IdType="pmc">PMC6202950</ArticleId>
            <ArticleId IdType="pubmed">30405609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voss F, van Beek LF, Schwudke D, Ederveen THA, van Opzeeland FJ, Thalheim D, Werner S, de Jonge MI, Hammerschmidt S. 2020. Lipidation of pneumococcal antigens leads to improved immunogenicity and protection. Vaccines (Basel)
8:310. 10.3390/vaccines8020310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/vaccines8020310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moffitt K, Howard A, Martin S, Cheung E, Herd M, Basset A, Malley R. 2015. T(H)17-mediated protection against pneumococcal carriage by a whole-cell vaccine is dependent on Toll-like receptor 2 and surface lipoproteins. Clin Vaccine Immunol
22:909–916. 10.1128/CVI.00118-15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CVI.00118-15</ArticleId>
            <ArticleId IdType="pmc">PMC4519727</ArticleId>
            <ArticleId IdType="pubmed">26041040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynolds JM, Pappu BP, Peng J, Martinez GJ, Zhang Y, Chung Y, Ma L, Yang XO, Nurieva RI, Tian Q, Dong C. 2010. Toll-like receptor 2 signaling in CD4+ T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity
32:692–702. 10.1016/j.immuni.2010.04.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2010.04.010</ArticleId>
            <ArticleId IdType="pmc">PMC2878917</ArticleId>
            <ArticleId IdType="pubmed">20434372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu YJ, Gross J, Bogaert D, Finn A, Bagrade L, Zhang Q, Kolls JK, Srivastava A, Lundgren A, Forte S, Thompson CM, Harney KF, Anderson PW, Lipsitch M, Malley R. 2008. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog
4:e1000159. 10.1371/journal.ppat.1000159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1000159</ArticleId>
            <ArticleId IdType="pmc">PMC2528945</ArticleId>
            <ArticleId IdType="pubmed">18802458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kauppi-Korkeila M, van Alphen L, Madore D, Saarinen L, Kayhty H. 1996. Mechanism of antibody-mediated reduction of nasopharyngeal colonization by Haemophilus influenzae type b studied in an infant rat model. J Infect Dis
174:1337–1340. 10.1093/infdis/174.6.1337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/174.6.1337</ArticleId>
            <ArticleId IdType="pubmed">8940229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takala AK, Eskola J, Leinonen M, Kayhty H, Nissinen A, Pekkanen E, Makela PH. 1991. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis
164:982–986. 10.1093/infdis/164.5.982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/164.5.982</ArticleId>
            <ArticleId IdType="pubmed">1940479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan MN, Xu Q, Pichichero ME. 2017. Protection against Streptococcus pneumoniae invasive pathogenesis by a protein-based vaccine is achieved by suppression of nasopharyngeal bacterial density during influenza A virus coinfection. Infect Immun
85:e00530-16. 10.1128/IAI.00530-16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.00530-16</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tobin JM, Nickolich KL, Ramanan K, Pilewski MJ, Lamens KD, Alcorn JF, Robinson KM. 2020. Influenza suppresses neutrophil recruitment to the lung and exacerbates secondary invasive pulmonary aspergillosis. J Immunol
205:480–488. 10.4049/jimmunol.2000067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.2000067</ArticleId>
            <ArticleId IdType="pmc">PMC7416629</ArticleId>
            <ArticleId IdType="pubmed">32522833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leng CH, Liu SJ, Chen HW, Chong P. 2015. Recombinant bacterial lipoproteins as vaccine candidates. Expert Rev Vaccines
14:1623–1632. 10.1586/14760584.2015.1091732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14760584.2015.1091732</ArticleId>
            <ArticleId IdType="pubmed">26420467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michel LV, Kaur R, Zavorin M, Pryharski K, Khan MN, LaClair C, O’Neil M, Xu Q, Pichichero ME. 2018. Intranasal coinfection model allows for assessment of protein vaccines against nontypeable Haemophilus influenzae in mice. J Med Microbiol
67:1527–1532. 10.1099/jmm.0.000827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/jmm.0.000827</ArticleId>
            <ArticleId IdType="pubmed">30136923</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
